

New Jersey Females

Cancer Site	Rates ^a		% Change ^b
	2022	2017-2019 avg.	
All Sites	458.5	456.1	▲ 0.5%
Breast	143.7	138.5	▲ 3.8% ^d
Lung and Bronchus	45.8	49.2	▼ 6.9% ^d
Colon and Rectum ^c	35.4	34.4	▲ 2.9%
Corpus and Uterus, NOS	31.4	32.2	▼ 2.5%
Thyroid	26.4	25.5	▲ 3.5%
Melanoma of the Skin	17.2	17.0	▲ 1.2%
Non-Hodgkin Lymphoma	17.2	18.0	▼ 4.4%
Pancreas	13.7	13.6	▲ 0.7%
Leukemia	12.3	12.6	▼ 2.4%
Ovary	11.4	11.2	▲ 1.8%

KEY FINDINGS

- The **overall** rate for new cancer cases (incidence) for females **increased** slightly in 2022 (+0.5%) compared to the average pre-COVID rates (2017-2019).
- The 10 leading cancer types among females were similar between 2022 and 2017-2019 with slight fluctuations. The top cancers were **breast**, followed by **lung** and **colorectal** cancers.
- Compared to the Pre- Covid 2017-2019 rates, in 2022:
 - **Lung cancer rates decreased significantly** by 6.9%.
 - **Non-Hodgkin lymphoma rates dropped** by 4.4%.
 - **Breast cancer rates increased significantly** by 3.8%.
 - **Thyroid cancer rates rose** by 3.5%.

Abbreviations: NOS = Not otherwise specified. **Source:** NJ State Cancer Registry December 2024 file, NJ Department of Health. ^aRates are per 100,000 and age-adjusted to the 2000 US Standard Population (age <1 and 90+-Census P25-1130). ^b A green down-arrow indicates a decrease in rates from the 2017-2019 average to 2022; a red up-arrow indicates an increase in rates between these two time periods. ^c Includes appendix. ^d Statistically significant change in rates at p <0.05. ^e Includes *in situ*. Statistics may change slightly as additional information is reported. **NOTE: 2022 rates for some cancers may reflect a decline, due to Covid-19 pandemic access to care disruptions.**

New Jersey Males

Cancer Site	Rates ^a		% Change ^b
	2022	2017-2019 avg.	
All Sites	519.6	535.9	▼ 3.0% ^d
Prostate	144.7	144.4	▲ 0.2%
Lung and Bronchus	48.3	56.7	▼ 14.8% ^d
Colon and Rectum ^c	44.8	44.1	▲ 1.6%
Urinary Bladder ^e	35.2	38.1	▼ 7.6% ^d
Melanoma of the Skin	28.1	28.2	▼ 0.4%
Non-Hodgkin Lymphoma	24.3	26.1	▼ 6.9% ^d
Kidney and Renal Pelvis	22.4	23.4	▼ 4.3%
Leukemia	20.8	20.9	▼ 0.5%
Pancreas	17.5	17.0	▲ 2.9%
Oral Cavity and Pharynx	16.9	17.2	▼ 1.7%

KEY FINDINGS

- The **overall** rate for new cancer cases (incidence) among males **decreased significantly** by 3% in 2022 compared to the average pre-COVID rates.
- The 10 leading cancer types have remained similar over recent years, with **prostate** cancer having the highest rate, followed by **lung** and **colorectal** cancers.
- Compared to the pre-COVID 2017-2019 rates, in 2022:
 - **Lung** cancer rates **decreased significantly** by approximately **15%**.
 - **Urinary bladder** cancer rates **decreased significantly** by 7.6%.
 - **Non-Hodgkin lymphoma** rates **decreased** by 6.9%.
 - **Kidney and renal pelvic** cancer incidence rates **decreased** by 4.3%.
- While **most** of the top 10 cancer rates **decreased** in 2022 compared to pre-COVID rates, **prostate, colorectal, and pancreatic** cancers slightly **increased**.

Abbreviations: NOS = Not otherwise specified. **Source:** NJ State Cancer Registry December 2024 file, NJ Department of Health. ^a Rates are per 100,000 and age-adjusted to the 2000 US Standard Population (age <1 and 90+-Census P25-1130). ^b A green down-arrow indicates a decrease in rates from the 2017-2019 average to 2022; a red up-arrow indicates an increase in rates between these two time periods. ^c Includes appendix. ^d Statistically significant change in rates at p <0.05. ^e Includes *in situ*. Statistics may change slightly as additional information is reported. **NOTE: 2022 rates for some cancers may reflect a decline due to COVID-19 pandemic access to care disruptions.**



The New Jersey State Cancer Registry (NJSCR) Data Guidelines contains comprehensive data analysis methods, race and ethnicity classification, population and mortality data sources, and additional information: [NJSCR Data Guidelines](#)
Looking for more cancer data? [NJSCR interactive cancer data](#)